Archives

Genetic alterations in the FGFR2 gene occur in various cancer types and represent a promising target for therapies. However, clinical responses to available therapies remained variable and unpredictable, making it difficult to select patients who would benefit from these types of treatments. An international team of researchers led by Jos Jonkers, group leader at the […]

Valentina presents her work in a presentation entitled “Uncovering novel targets for therapy in T-cell acute lymphoblastic leukemia using phosphoproteomics” at a Cell Signaling Webinar on Post Translational Modification next Tuesday June 14th at 15:00.

On May 24 the Netherlands Proteomics PLatfrom gathered for its 20th anniversary meeting. It was a fantastic meeting with ~ 85 participants to which we contributed two talks. See here for the program https://www.netherlandsproteomicsplatform.nl/2022-spring-meeting/

It was an honour and great pleasure to speak at the joint German Proteomics Forum -European Proteomics Association meeting in Leipzig on phosphoproteomics for precision medicine. See here for the program full of great science : https://www.proteomic-forum.com/programme/scientific-programme

The next NPP meeting will be held on Tuesday 24 May 2022 in conference center ‘De Driehoek’ in Utrecht! Join us for an exciting program with contributions from proteomics labs all around the country. Also, there will be lots of opportunities to interact with friends and colleagues. The scientific program is here.

The Journal of Experimental & Clinical Cancer Research (JECCR) has congratulated Connie Jimenez on authoring one of the most-downloaded papers published in the journal during 2021 (‘High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer’). Since publishing, the article has been downloaded 3144 times. Go see the article

Our study published Feb. 25 in Nature Communications shows that phosphoproteomic profiling can discover novel targets for therapy for T-ALL and it can guide the design of treatment combination strategies when a single therapy is not sufficient. The analysis of active proteins gives us a more complete picture of the leukemia and allows for selection […]

Zhu T, Zhu Y, Xuan Y, Gao H, Cai X, Piersma SR, Pham TV, Schelfhorst T, Haas RRGD, Bijnsdorp IV, Sun R, Yue L, Ruan G, Zhang Q, Hu M, Zhou Y, Van Houdt WJ, Le Large TYS, Cloos J, Wojtuszkiewicz A, Koppers-Lalic D, Böttger F, Scheepbouwer C, Brakenhoff RH, van Leenders GJLH, Ijzermans JNM, […]

16 November 2021 15:45 Fine-tuning prediction of response and survival in acute myeloid leukemia PhD defence by D.G.J. Cucchi

This progress report 2018-2021 covers proteomics research of the OncoProteomics Laboratory (OPL) and collaborators, as well as proteomics activities performed in the context of our function as Proteomics Core Facility. It harbors information on our mass spectrometry infrastructure and proteomics expertise, output, academic activities and includes summaries of running core and collaborative projects.